Patent ID: 6635671
Filing Date: 2003-10-21
Classification: A61K,A61P

Abstract:
A method for the prophylaxis or treatment of a disease or medical condition having an etiology associated with the increased stability of mRNA which contains one or more mRNA instability sequences, comprising administering to a human or animal patient an effective amount of a compound of Formula II: whereinR1 is H, OH, halogen, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COOâ€”; R2 is OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COOâ€”; R3 is H, OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COOâ€”; â€”aâ€”bâ€” is â€”CHR7â€”CHR8â€” or cis or trans â€”CR7&boxH;CR8â€”; wherein R7 and R8 are the same or different and are H, OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COOâ€”, or â€”aâ€”bâ€” is â€”CHR7â€”CHR8â€” and R7 and R8 together with O form an epoxide bridge; c is >CHâ€”OH, >C&boxH;O or >CH2; â€”dâ€”eâ€” is â€”CHR7â€”CHR8â€” or cis or trans â€”CR7&boxH;CR8â€”, wherein R7 and R8 are the same or different and are H, OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COOâ€”, and â€”fâ€”gâ€” is â€”CH2â€”CH2â€”, or cis or trans â€”CH&boxH;CHâ€”, or a pharmaceutically acceptable salt thereof or a physiologically-hydrolysable and -acceptable ester thereof, wherein said compound induces degradation of the mRNA, provided that the disease or medical condition is not one with an etiology associated with or comprising excessive cytokine release.